Search Results
Your search for ASCO,ASCO matches 20829 pages
Showing 2401 - 2450Study Examines Stress and Social Support for LGBTQI Patients With Cancer and Their Caregivers
Investigators have uncovered how current and historical experiences—including discrimination, violence, family rejection, and exclusion—have created a legacy of distress and fear, adversely impacted trust in health-care professionals, and resulted in unmet needs in cancer survivorship and care for...
Low Income Linked to High Recurrence Risk, Poorer Survival in Patients With ER-Positive Breast Cancer
Patients with early-stage estrogen receptor (ER)-positive breast cancer who live in low-income neighborhoods may be more likely to have more aggressive tumor biology and significantly lower overall survival than those living in higher-income neighborhoods, according to a new study published by Ma...
Expert Point of View: Robert Rifkin, MD
Smoldering myeloma is an asymptomatic plasma cell disorder with a heterogeneous clinical behavior. Two trials presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition investigated early intervention for smoldering multiple myeloma, aiming for a “curative strategy”...
Pediatric Patients With ALL Living Along the Texas-Mexico Border May Experience Lower Rates of Survival
Investigators have found that pediatric patients with acute lymphoblastic leukemia (ALL) who lived along the Texas-Mexico border were more likely to die within 5 years than those living in other areas of the state, according to a new study published by Castellanos et al in Cancer. Background...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
TRITON3: Rucaparib vs Physician’s Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM Alterations
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the entire population of patients with metastatic...
President Biden Announces Key Appointments to National Cancer Advisory Board
On February 2, 2023, President Joseph Biden announced his intent to appoint six members to the National Cancer Advisory Board (NCAB). The NCAB plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. The NCAB...
Grateful to Be Alive
Although there is no history of cancer in my family, I guess it isn’t surprising that I would develop an aggressive form of melanoma on my scalp after years of ultraviolet radiation from sun exposure. Still, getting the diagnosis was devastating. I first noticed a small lump on the top of my head ...
Yale Study Indicates Older Patients Are Excluded From Progress Against Lung Cancer
The widespread use of immune checkpoint inhibitors has led to significant benefits in younger patients with advanced lung cancer; however, older patients have not experienced similar survival benefits, according to research from Yale Cancer Center. The study was published in JAMA Oncology.1 “There ...
Toni K. Choueiri, MD, on Renal Cell Carcinoma: Potential Predictive Biomarkers of Treatment Efficacy
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses a biomarker analysis from the phase III CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib for the treatment of patients with advanced renal cell carcinoma. The ongoing study aims to identify a predictive biomarker that...
Adding Talazoparib to Enzalutamide Extends Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
Nivolumab After Surgical Resection Improves Disease-Free Survival for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
Adjuvant therapy with the immune checkpoint inhibitor nivolumab following surgery improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma, according to new findings presented by Matthew D. Galsky, MD, FASCO, and colleagues at the 2023 ASCO Genitourinary...
Single-Arm Phase II Noninferiority Trial Evaluates Active Surveillance vs Cystectomy Following Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma
Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid a cystectomy and achieve a 2-year metastasis-free survival, according to new findings presented by Daniel M. Geynisman, MD, and colleagues at the 2023 ASCO Genitourinary...
Intensified Drug Regimen Added to Standard of Care Improves Outcomes in Subset of Patients With High-Risk Prostate Cancer
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
Emerging Second- and Third-Line Therapies for Unresectable and Metastatic Melanoma
This is Part 4 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss the second- and third-line therapy options for unresectable and metastatic melanoma. The...
First-Line Therapy for Metastatic Malignant Melanoma
This is Part 3 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss the first-line treatment of metastatic melanoma. The patient is a 32-year-old woman...
Neoadjuvant Therapy in Malignant Melanoma
This is Part 2 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss current adjuvant treatment options in malignant melanoma. The patient is a 67-year-old man ...
Adjuvant Therapy in Malignant Melanoma
This is Part 1 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss current adjuvant treatment options in malignant melanoma. The patient is a 67-year-old man ...
Cancer Symptom Algorithm May Aid Oncologists in Predicting Which Patients Are at Risk for Unplanned ED Visits
Researchers have found that an algorithm that calculates patient-reported symptom complexity scores may help oncologists identify patients who are at an increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care and reduced health-care ...
TALAPRO-2: Talazoparib Plus Enzalutamide Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free survival vs the current standard of care for patients with metastatic...
Robert A. Brodsky, MD, Begins Term as 2023 ASH President
Robert A. Brodsky, MD, a renowned expert in classical hematology, will serve as President of the American Society of Hematology (ASH) for a year-long term through December 2023. Dr. Brodsky is Professor of Medicine and Oncology and Director of Hematology at Johns Hopkins University School of...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Expert Point of View: Bita Fakhri, MD, MPH
Moderator of the session on the CLL2-GIVe regimen, Bita Fakhri, MD, MPH, Assistant Professor of Medicine at Stanford Medicine, California, said that findings from the ongoing, phase III CLL13 trial will ultimately determine which regimen is appropriate for patients with high-risk chronic...
Expert Point of View: Emily K. Curran, MD
Moderator of the session, Emily K. Curran, MD, Assistant Professor of Internal Medicine at the University of Cincinnati Cancer Center, in Ohio, said the data presented by Dr. Short and colleagues demonstrated very impressive event-free and overall survival rates, especially for a disease that has...
Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...
Expert Point of View: Amir T. Fathi, MD
Amir T. Fathi, MD, Associate Professor of Medicine at Harvard Medical School and Director of the Leukemia Program at Massachusetts General Cancer Center, said the approach of intensifying chemotherapy with the addition of venetoclax is one of several being studied in the upfront setting....
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
Addition of Venetoclax to Intensive Chemotherapy Yields Durable Responses in Younger Patients With High-Risk AML
Longer follow-up of a phase II study of venetoclax combined with cladribine, idarubicin, and cytarabine (CLIA) as a front-line induction regimen for younger patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) shows a pattern of durable efficacy consistent with...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Ponatinib May Be More Effective Than Imatinib for Newly Diagnosed Patients With Ph-Positive ALL
In newly diagnosed patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy. These results were presented by Jabbour et al during the February ASCO Plenary Series session...
Is a Diet Higher in Plant-Based Foods Associated With a Lower Risk of Prostate Cancer Progression and Recurrence?
Patients with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of disease progression and a 53% lower risk of recurrence compared with those who had the lowest amounts of plants in their diets. The diet assessments were based on...
New Study Calls for LGBTQIA+ Community Inclusion in Stem Cell Donor Recruitment
Researchers have highlighted the barriers to stem cell donation impacting LGBTQIA+ individuals and the efforts needed to build more inclusive donor recruitment practices and offered guidance for donor recruitment organizations, registries, and transplant centers worldwide to advance a more...
Decline in PSA Level After Treatment With Enzalutamide: Effect on Metastasis and Survival
A decline in prostate-specific antigen (PSA) levels following treatment with the androgen receptor inhibitor enzalutamide may effectively predict improved survival rates among patients with nonmetastatic castration-resistant prostate cancer, according to a post hoc analysis of data from the PROSPER ...
New Predictive Epidemiologic Model May Identify Individuals at High Risk for Endometrial Cancer
Investigators have developed a predictive model that may be used in research and eventually clinical settings to identify individuals at high risk of developing endometrial cancer who would benefit from screenings, according to a report published by Shi et al in the Journal of the National Cancer...
Pancreatic Cancer Rates May Be Rising Faster Among Younger Women Than Younger Men
Investigators have confirmed that rates of pancreatic cancer are rising overall, but they are rising faster among younger female patients—particularly among patients who identified as Black—than among male patients of the same age, according to a new study published by Abboud et al in...
Lack of Resources May Be Associated With Increased Mortality Rates Among Pediatric Cancer Survivors
Investigators have found that socioeconomic deprivation, the presence of modifiable chronic health conditions, and frailty may all independently be associated with increased rates of late mortality among pediatric cancer survivors, according to a new study published by Ehrhardt et al in JAMA...
Dietary Intervention May Help Reduce Chronic Fatigue, Improve Quality of Life for Cancer Survivors
Researchers have discovered that dietary interventions may help reduce fatigue, improve diet quality, and lead to an overall better quality of life for cancer survivors, according to a new study published by Weinhold et al in Nutrition and Cancer. Background For many cancer survivors, the side...
FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
On February 9, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient (dMMR), recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or...
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy: Health-Related Quality-of-Life Outcomes From a Randomized Clinical Trial
Guest Editor’s Note: Chemotherapy-induced peripheral neuropathy is a common and potentially debilitating side effect of neurotoxic chemotherapy. It worsens the quality of life for many cancer survivors, with limited treatment options. In this installment of The ASCO Post’s Integrative Oncology...
The Beauty and the Beast of Cancer
The most humbling—and fortunate—experience I’ve had since I was diagnosed with osteosarcoma 13 years ago at the age of 43 was being treated in the pediatric wing of a major cancer center in New York City. It is pretty difficult to feel sorry for yourself when you are sitting next to a 14-year-old...
Raised in Africa, Surgeon Kristin Flowers, MD, Continues the Tradition of Service in a Rural Hospital in Alaska
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kristin Flowers, MD, a general surgeon at Tanana Valley Clinic at Fairbanks Memorial Hospital in rural Alaska. Dr. Flowers’ surgical areas of interest include treating...
Traveling the World at an Early Age Gave Perspective and Balance to Future Oncology Leader Derek Raghavan, MD, PhD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Founding President of the Levine Cancer Institute. Established in 2011, the Levine Cancer Institute is part of Atrium Health (formerly the...
MD Anderson’s Guillermina Lozano, PhD, Receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, PhD, Chair of Genetics at The University of Texas MD Anderson Cancer Center, Houston, has received the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association...
Terry Hyslop, PhD, Joins SKCC as Cancer Risk and Control Program Co-Leader and Center for Health Equity Director
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently welcomed transdisciplinary population health researcher Terry Hyslop, PhD, as Co-Leader of the Cancer Risk and Control Program. Dr. Hyslop is returning to SKCC from the Duke Cancer Institute, where she served as Professor of...
KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials
KRAS G12C–mutated colorectal cancer represents 3% to 4% of metastatic colorectal cancers. Like other KRAS-mutated metastatic colorectal cancers, this group of patients represents a patient population with an unmet need, with limited options beyond two lines of therapy. In contrast to other KRAS...
New JCO Oncology Practice Special Series Highlights Current State of Team-Based Care, Innovations, and Future Direction
What is team-based cancer care, and how has it evolved over the past decade? A special series in ASCO’s JCO Oncology Practice highlights transformations in team-based delivery models within the cancer care system and their potential direction. A carefully curated series of 15 peer-reviewed articles ...
